ACETAZOLAMIDE capsule extended release

Χώρα: Ηνωμένες Πολιτείες

Γλώσσα: Αγγλικά

Πηγή: NLM (National Library of Medicine)

Δραστική ουσία:

ACETAZOLAMIDE (UNII: O3FX965V0I) (ACETAZOLAMIDE - UNII:O3FX965V0I)

Διαθέσιμο από:

KAISER FOUNDATION HOSPITALS

INN (Διεθνής Όνομα):

ACETAZOLAMIDE

Σύνθεση:

ACETAZOLAMIDE 500 mg

Τρόπος διάθεσης:

PRESCRIPTION DRUG

Καθεστώς αδειοδότησης:

Abbreviated New Drug Application

Αρχείο Π.Χ.Π.

ACETAZOLAMIDE - ACETAZOLAMIDE CAPSULE, EXTENDED RELEASE
KAISER FOUNDATION HOSPITALS
----------
ACETAZOLAMIDE EXTENDED-RELEASE CAPSULES
DESCRIPTION
Acetazolamide extended-release capsules are an inhibitor of the enzyme
carbonic anhydrase.
Acetazolamide is a white to faintly yellowish white crystalline,
odorless powder, weakly acidic, very
slightly soluble in water and slightly soluble in alcohol. The
chemical name for acetazolamide is N-(5-
Sulfamoyl-1,3,4-thiadiazol-2-yl)acetamide and has the following
chemical structure:
MW 222.24 C H N O S
Each acetazolamide extended-release capsule intended for oral
administration contains 500 mg of
acetazolamide. In addition, each capsule contains the following
inactive ingredients: ammonio
methacrylate copolymer dispersion type A and B, FD&C yellow #6,
gelatin, microcrystalline cellulose,
sodium lauryl sulfate, talc and titanium dioxide. The capsule is
printed with black pharmaceutical ink
which contains black iron oxide as a coloring agent.
CLINICAL PHARMACOLOGY
Acetazolamide is a potent carbonic anhydrase inhibitor, effective in
the control of fluid secretion (e.g.,
some types of glaucoma), in the treatment of certain convulsive
disorders (e.g., epilepsy) and in the
promotion of diuresis in instances of abnormal fluid retention (e.g.,
cardiac edema).
Acetazolamide is not a mercurial diuretic. Rather, it is a
non-bacteriostatic sulfonamide possessing a
chemical structure and pharmacological activity distinctly different
from the bacteriostatic
sulfonamides.
Acetazolamide is an enzyme inhibitor that acts specifically on
carbonic anhydrase, the enzyme that
catalyzes the reversible reaction involving the hydration of carbon
dioxide and the dehydration of
carbonic acid. In the eye, this inhibitory action of acetazolamide
decreases the secretion of aqueous
humor and results in a drop in intraocular pressure, a reaction
considered desirable in cases of
glaucoma and even in certain non-glaucomatous conditions. Evidence
seems to indicate that
acetazolamide has utility as an adjuvan